A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks
Titel:
A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks
Auteur:
O’Brien, M.E.R. Myerson, J.S. Coward, J.I.G. Puglisi, M. Trani, L. Wotherspoon, A. Sharma, B. Cook, G. Ashley, S. Gunapala, R. Chua, S. Popat, S.